Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

NCT03543969 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

14

Enrollment

OTHER

Sponsor class

Conditions

Melanoma (Skin)
Skin Cancer
Skin Melanoma
Skin Carcinoma

Interventions

DRUG: Encorafenib
DRUG: Binimetinib
DRUG: Nivolumab

Sponsor

H. Lee Moffitt Cancer Center and Research Institute